Is MRVL Stock a Buy, Sell or Hold at a P/E Multiple of 7.15X?
Given MRVL's discounted valuation, investors might be wondering: Is this an opportunity to buy, or are there deeper challenges that could keep the stock in check?
MRVL Forward 12 Months (P/E) Valuation Chart
Product Innovation Positions MRVL for Sustainable Growth
What makes Marvell Technology's low P/E value more attractive is its robust business prospects. Due to the proliferation of AI and high performance computing among data centers and hyperscalers, MRVL is experiencing massive traction in custom Application Specific Integrated Circuits, Custom high bandwidth memory Compute Architecture, Co-Packaged Optics Platform and Multi-Die Packaging Platform products.
As data centers perform a growing number of AI-related tasks, improvements in networking, interconnect, processing and storage capabilities, requiring high-performance semiconductor solutions become crucial. Marvell Technology is capitalizing on this opportunity with 800G PAM, 400ZR DCI, and 1.6T PAM digital signal processing products. This growth is evident in Marvell Technology's data center segment, which has taken the lead among all its segments with 76% year-over-year revenue growth in the first quarter of fiscal 2026.
Marvell Technology also plans to expand its customer base among hyperscaler customers that seek to stand out, cut expenses and want to gain more control over their AI infrastructure. Marvell Technology has collaborated with NVIDIA and leveraged the latter's NVLink Fusion platform to build comprehensive rack-scale AI solutions to meet the needs of hyperscalers.
Furthermore, the shift from copper to optical connectivity in AI infrastructure represents a massive growth opportunity for Marvell Technology's Co-Packaged Optics technology. Marvell Technology is also experiencing a recovery among its enterprise networking and carrier infrastructure segments on the back of the demand rebound. However, Marvell Technology is also facing some challenges.
With all these factors at play, the Zacks Consensus Estimate for Marvell Technology's 2026 revenues is pegged at $8.2 billion, indicating year-over-year growth of 42.6%. The consensus mark for earnings is pegged at $2.79 per share, suggesting a whopping 77.7% year-over-year increase.
Key Challenges Faced by Marvell Technology
Marvell is experiencing traction in its AI-focused custom silicon semiconductor business, but the margin in this business is half the story, as the margin in this business is fundamentally lower, affecting MRVL's gross margin. MRVL's custom AI silicon, including XPUs, is lowering MRVL's gross margins due to higher costs associated with manufacturing these chips.
The ongoing macroeconomic uncertainties, like the U.S. government's evolving stance toward China, from which MRVL gained about 43% of its fiscal 2025 total revenues, are also a concern for the company. Investors' skepticism has also been intensified by the fear of sanctions and persistent tariff threats to China, where Marvell Technology owns research and development facilities. Furthermore, softness in MRVL's consumer end market due to volatility in gaming demand and lumpy order patterns in the industrial business has added to investor concerns.
Marvell Technology also faces intense competition from Broadcom AVGO and Advanced Micro Devices AMD in the AI accelerator space and Micron Technology MU in the HBM space. Advanced Micro Devices is a strong player in the custom silicon solutions and AI accelerator space with its semi-custom SoC offerings and Instinct Accelerators that power numerous data centers. Advanced Micro Devices' reconfigurable Alveo Adaptable Accelerator Cards are used to speed up compute-intensive applications in data centers.
Broadcom's advanced 3.5D XDSiP packaging platform is specifically designed to enhance the performance and efficiency of custom AI XPUs for AI accelerators. Micron Technology is also riding a powerful wave of demand for high-bandwidth memory (HBM) and DRAM products, especially as AI workloads surge. Micron Technology has made significant strides in AI-optimized memory solutions, with its HBM3E products gaining attention for their superior power efficiency and bandwidth. These factors have weighed on MRVL stock's performance.
Stock Price Performance of MRVL
Marvell Technology has underperformed the Zacks Electronics - Semiconductors industry in the year-to-date period by losing 32.6%.
Marvell Technology YTD Performance Chart
Conclusion: Hold MRVL Stock for Now
Marvell Technology is facing several headwinds, including geopolitical tension, shrunken margins and growing competition across its end markets. However, the company has strong long-term fundamentals supported by its strong foothold in the data center and high-speed networking market.
Considering all these factors, we suggest that investors should retain this Zacks Rank #3 (Hold) stock at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report
Micron Technology, Inc. (MU): Free Stock Analysis Report
Marvell Technology, Inc. (MRVL): Free Stock Analysis Report
Broadcom Inc. (AVGO): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
11 minutes ago
- Globe and Mail
Femasys Revenue Jumps 85 Percent in Q2
Key Points Revenue surged 84.8% to $0.41 million (GAAP) in Q2 2025, far outpacing consensus estimates (GAAP) but still early-stage in scale. FemBloc gained its first-ever European approval; FemaSeed and FemVue secured new regulatory clearances and partnerships. Net loss (GAAP) narrowed slightly to $4.59 million, while cash reserves (GAAP) dropped to $3.22 million, bringing a near-term cash crunch. These 10 stocks could mint the next wave of millionaires › Femasys (NASDAQ:FEMY), a women's health medical technology firm developing permanent birth control and fertility solutions, released its second quarter 2025 results on August 8, 2025. The earnings report was marked by strong revenue growth to $0.41 million (GAAP)—an 84.8% jump in GAAP sales from the prior year period—driven by accelerating early-stage sales of FemaSeed intratubal insemination devices and FemVue diagnostic systems. This figure (GAAP revenue of $409,268) came in far above analyst estimates. The company posted a GAAP net loss of $4.59 million, a slight improvement from the $4.68 million GAAP net loss in Q2 2024. Diluted earnings per share (GAAP) was slightly better than analyst estimates at $(0.16). Despite clear commercial and regulatory progress, continued operating losses and a $3.22 million cash balance as of June 30, 2025 mean Femasys will need additional funding within the next quarter to sustain operations. Source: Analyst estimates for the quarter provided by FactSet. Femasys at a Glance and Business Focus Femasys designs and commercializes non-surgical products for women's reproductive health needs. Its main portfolio spans permanent birth control devices—most notably the FemBloc system—and fertility-related solutions like FemaSeed and FemVue. Recent company focus has been on winning new regulatory approvals, especially for FemBloc, and moving early-stage products from research and development into wider commercial sales. Key success factors for Femasys include clearing regulatory hurdles in each market, gaining adoption from clinics and patients, and forming the right distribution partnerships. Protecting its intellectual property is also essential given the specialized nature of its technology. Quarter Highlights: Financial and Product Progress Revenue (GAAP) climbed 84.8%, driven by sales of FemaSeed and FemVue. A roughly $400,000 order from Spain signals a pivotal step in international expansion efforts. Sales of FemaSeed intratubal insemination devices and FemVue diagnostic products—tools that facilitate fertility assessment—drove most of the top-line gain. Together, these products represent the company's early moves beyond the U.S. market. On the regulatory front, Femasys achieved a series of important clearances: FemBloc received its first European approval, marking the first global regulatory sign-off for a non-surgical permanent birth control option in the company's portfolio. FemaSeed and FemVue also gained approvals in Australia and New Zealand, expanding potential markets and laying groundwork for future sales. Ongoing enrollment in U.S. pivotal trials for FemBloc continues, which will be crucial for future coverage and adoption in the American healthcare market. The company expanded its reach through new partnerships. It announced a relationship with the Carolinas Fertility Institute, an eight-clinic network in the U.S, to offer FemaSeed to more patients. Distribution partnerships in Spain will support further commercialization of FemBloc. Femasys also shored up its patent portfolio, receiving notice of intent to grant new patents in Europe and the U.S. for FemBloc and FemaSeed, maintaining its lead in the emerging non-surgical device category. Financially, the net loss (GAAP) narrowed slightly to $4.59 million, reflecting both increased sales and a 28.4% drop in research and development expense as products transition to the commercial phase. However, cash burn remained high: the $3.22 million cash balance at June 30, 2025 gives the company only enough runway to operate into early fourth quarter, without additional funding. The company raised $4.5 million in new equity but continued operating losses have quickly reduced available resources. Inventory increased 71.8% year-to-date (as of June 30, 2025), showing strategic preparation for expected sales but also a concentration of capital in unsold goods. The share count rose from 23,355,926 as of December 31, 2024, to 32,575,407 as of June 30, 2025. Femasys does not currently pay a dividend. Looking Forward Femasys management did not provide specific revenue or earnings targets for the coming quarters or for fiscal 2025. Leadership emphasized that the next stages will focus on translating recent approvals and pilot orders into routine commercial adoption, particularly in the European Union and new Asia-Pacific markets, and continuing to build distribution and clinic partnerships. Given the current cash position as of June 30, 2025, the company expects its cash and cash equivalents will be sufficient to fund operations into the early fourth quarter of 2025. The expanding international footprint and product pipeline, along with progress on intellectual property protection, remain important areas for investors to monitor in the coming periods. FEMY does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,047%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
36 minutes ago
- Globe and Mail
After Skyrocketing Over 3,000% in 5 Years, Can MicroStrategy Stock Continue to Rise Higher?
Key Points MicroStrategy is the largest corporate holder of Bitcoin, and it's not even close. The company recently reported a mammoth profit due to gains on digital assets. Its Bitcoin-buying strategy has been working tremendously well, and other companies may follow suit. 10 stocks we like better than Strategy › Did you know that in five years, Bitcoin has risen more than 870% in value? It's a staggering return given that the S&P 500 is up just 91% over that same period. That's still a solid return, but it pales in comparison to Bitcoin. But what may be even more surprising is that a company that has simply been loading up on Bitcoins has been a far better buy than the cryptocurrency itself. MicroStrategy (NASDAQ: MSTR), which now goes by just "Strategy," has climbed a remarkable 3,000% in five years. It hasn't been experiencing huge sales growth or become a top artificial intelligence (AI) company. Instead, it has just been accumulating Bitcoins, and its enthusiasm for the cryptocurrency has made it a red-hot stock for retail investors to buy. However, with the company already accumulating such massive gains in a short time frame, is it due for a crash or at least a correction? Or could it still be a good buy today? More companies are following the same blueprint Strategy's remarkable returns over the years haven't gone unnoticed by other businesses. More companies are also eagerly investing in the top digital currency in the world as they try to appeal to retail investors. Social media stock Trump Media and Technology Group has recently announced it bought $2 billion in Bitcoin. The stock, largely a speculative play, is likely hoping a similar bullishness in crypto sends its valuation soaring. It's now the fifth-largest corporate holder of Bitcoin. Some other notable names that have accumulated significant amounts of Bitcoin include Block and Tesla. For Strategy, it is still far and away the leader, owning nearly 629,000 Bitcoins as of Aug. 4. The next-largest corporate position belongs to crypto mining company Mara Holdings, which has 50,000 Bitcoins. But the sheer success of Strategy's approach could entice other businesses to do the same and start accumulating significant holdings of Bitcoin as well. If the novelty of Strategy's stock wears off, that could result in less bullishness and excitement, potentially leading to more muted gains for it in the future. A disconnect with fundamentals could make the stock ripe for a sell-off Loading up on Bitcoins has enabled Strategy's valuation to grow to a market cap of $110 billion today. It's large enough to now be part of the Nasdaq 100 index, which is made up of the top non-financial stocks on the exchange. (Strategy is technically involved in providing companies with business intelligence and analytics software.) A quick look at some valuation metrics highlights just how egregiously priced the stock has become: Strategy trades at more than 200 times its revenue, and its estimated forward price-to-earnings multiple, which is based on analyst estimates, is over 1,200. In its most recent quarter, which ended on June 30, Strategy reported a monstrous net income of more than $10 billion despite only generating $115 million in revenue. The boost came, of course, from its position in digital assets. Strategy reported an unrealized gain of over $14 billion during the period, which was offset partly by a nearly $4 billion provision for income taxes. The business has benefited significantly from Bitcoin's rising valuation and the digital currency hitting record levels this year, but with such a large valuation and enormous volatility on its financials, it makes Strategy a highly speculative investment. Can Strategy's stock still be a good buy? If Bitcoin continues rallying and Strategy keeps on to its tally of Bitcoins, it wouldn't surprise me to see the crypto stock rise even higher in the future. The temptation may be to think that Bitcoin is destined to continue going higher, but that's by no means a sure thing. Without strong fundamentals to fall back on, Strategy is simply too volatile and risky of an investment to own. It has achieved significant gains in recent years, but that doesn't mean that the stock's future performance will mirror that. Unless you're a crypto enthusiast with a high tolerance for risk, you're likely better off avoiding Strategy's stock, as it could take you on a roller-coaster ride. Should you invest $1,000 in Strategy right now? Before you buy stock in Strategy, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Strategy wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin, Block, and Tesla. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.
Globe and Mail
41 minutes ago
- Globe and Mail
KOIL Energy Solutions Schedules Q2 2025 Earnings Release and Conference Call
HOUSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Koil Energy Solutions, Inc. (OTCQB: KLNG), announced today that it will file its Quarterly Report on Form 10-Q for the second quarter of 2025 on Thursday, August 14, 2025. KOIL will host an investor conference call to review its second quarter of 2025 results on Thursday, August 14, 2025, at 10:00 am Eastern Time. Interested parties may listen to the call through a webcast link or using the dial in numbers. (See below details.) GENERAL EVENT DETAILS Title: Koil Energy Second Quarter 2025 Earnings Conference Call Date: 08/14/2025 Start time: 10:00am EDT - Start of live event PARTICIPANT WEBCAST LINK: PARTICIPANT DIALS: Participant Toll-Free: 1-833-630-1956 Participant Toll/Int'l: 1-412-317-1837 Password: Koil Energy Solutions call Replay Dials: (available up to 7 days after the call) Replay Toll-Free: 1-877-344-7529 Replay Toll/Int'l: 1-412-317-0088 Replay Password: 3264769 The earnings release and a replay of the conference call will also be available on the Company's website, under the "Investors" section. About Koil KOIL is a leading energy services company offering subsea equipment and support services to the world's energy and offshore industries. Investor Relations Contact: ir@ 281-862-2201
